The GMRF Clinical Trials Unit will soon be recruiting for the following lung clinical trial:

PROTOCOL: AMG20200041 (PI: DR KENNETH o’Byrne) (not yet recruiting)

Protocol Title: A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) 

Lay Title: Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First-Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLphi-305) 

Click here for more information

Protocol: GO45006 (PI: Professor Kenneth O’Byrne)

Protocol Title: Study Title: A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Lay Title: A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)

Click here for more information

PROTOCOL: IM043-004 (PART 2) (PI: DR KENNETH O’BYRNE)

Protocol Title: A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Lay Title: A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Click here for more information